JP2020530302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530302A5 JP2020530302A5 JP2020507609A JP2020507609A JP2020530302A5 JP 2020530302 A5 JP2020530302 A5 JP 2020530302A5 JP 2020507609 A JP2020507609 A JP 2020507609A JP 2020507609 A JP2020507609 A JP 2020507609A JP 2020530302 A5 JP2020530302 A5 JP 2020530302A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- clec9a
- clec9a binding
- appendix
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023033005A JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2024161448A JP7746499B2 (ja) | 2017-08-09 | 2024-09-18 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2025154319A JP2025181864A (ja) | 2017-08-09 | 2025-09-17 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542944P | 2017-08-09 | 2017-08-09 | |
| US62/542,944 | 2017-08-09 | ||
| PCT/US2018/045742 WO2019032662A1 (en) | 2017-08-09 | 2018-08-08 | CLEC9A BINDING AGENTS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023033005A Division JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530302A JP2020530302A (ja) | 2020-10-22 |
| JP2020530302A5 true JP2020530302A5 (enExample) | 2021-09-16 |
| JP7327885B2 JP7327885B2 (ja) | 2023-08-16 |
Family
ID=65272496
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507609A Active JP7327885B2 (ja) | 2017-08-09 | 2018-08-08 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2023033005A Active JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2024161448A Active JP7746499B2 (ja) | 2017-08-09 | 2024-09-18 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2025154319A Pending JP2025181864A (ja) | 2017-08-09 | 2025-09-17 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023033005A Active JP7559114B2 (ja) | 2017-08-09 | 2023-03-03 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2024161448A Active JP7746499B2 (ja) | 2017-08-09 | 2024-09-18 | Ｃｌｅｃ９ａ結合物質およびその使用 |
| JP2025154319A Pending JP2025181864A (ja) | 2017-08-09 | 2025-09-17 | Ｃｌｅｃ９ａ結合物質およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12091463B2 (enExample) |
| EP (1) | EP3665303A4 (enExample) |
| JP (4) | JP7327885B2 (enExample) |
| KR (3) | KR20250049459A (enExample) |
| CN (2) | CN117924493A (enExample) |
| AU (2) | AU2018313810B2 (enExample) |
| BR (1) | BR112020002706A2 (enExample) |
| CA (1) | CA3069992A1 (enExample) |
| IL (1) | IL272524B1 (enExample) |
| MX (3) | MX2020001513A (enExample) |
| SG (1) | SG11202001063QA (enExample) |
| WO (1) | WO2019032662A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12655186B2 (en) | 2018-01-26 | 2026-06-16 | Orionis Biosciences, Inc. | Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2 |
| CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| WO2020041720A1 (en) | 2018-08-24 | 2020-02-27 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| KR20210057124A (ko) * | 2018-09-11 | 2021-05-20 | 암브룩스, 인코포레이티드 | 인터류킨-2 폴리펩타이드 접합체 및 그의 용도 |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| WO2020198665A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| CN113840833B (zh) * | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| EP4034146A4 (en) * | 2019-09-26 | 2024-03-06 | Orionis Biosciences, Inc. | CONJUGATED CHIMERIC PROTEINS |
| CA3163358A1 (en) | 2019-12-03 | 2021-06-10 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| KR102930110B1 (ko) | 2020-04-20 | 2026-02-25 | 에스케이온 주식회사 | 배터리 모듈 |
| AU2021341508A1 (en) | 2020-09-10 | 2023-05-25 | Precirix N.V. | Antibody fragment against fap |
| EP4225373A4 (en) | 2020-10-07 | 2025-01-08 | Dren Bio, Inc. | ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF |
| JP2024504903A (ja) * | 2021-01-29 | 2024-02-02 | 中外製薬株式会社 | 細胞死が観察される組織において特異的に作用する分子 |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CN114702588B (zh) * | 2022-04-27 | 2022-11-22 | 博际生物医药科技(杭州)有限公司 | 抗Nectin-4抗体和双特异性抗体 |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| WO2026015864A1 (en) * | 2024-07-12 | 2026-01-15 | Outpace Bio, Inc. | Cd8 binding polypeptides and methods of use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489116B1 (en) | 1989-08-22 | 1994-04-06 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| JP2012521199A (ja) * | 2009-03-23 | 2012-09-13 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 免疫応答を調節するための化合物および方法 |
| RU2583876C2 (ru) | 2009-08-17 | 2016-05-10 | Роше Гликарт Аг | Иммуноконъюгаты направленного действия |
| CN102497885A (zh) | 2009-09-10 | 2012-06-13 | 赛托斯生物技术公司 | 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途 |
| RU2577299C2 (ru) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| WO2013107791A1 (en) | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| US20150132302A1 (en) | 2012-05-01 | 2015-05-14 | The University Of Sydney | Vaccine and uses thereof |
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| CN114732017A (zh) * | 2013-04-29 | 2022-07-12 | 阿格罗塞文公司 | 包含结合至鞘脂的抗体的农用化学组合物 |
| ITTO20130563A1 (it) * | 2013-07-05 | 2015-01-06 | Savio Spa | Dispositivo per l'apertura e la chiusura di un'anta oscillante apribile verso l'esterno |
| KR102322510B1 (ko) | 2013-07-18 | 2021-11-08 | 브이아이비 브이지더블유 | 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인 |
| CA2918518C (en) | 2013-07-19 | 2022-08-16 | Universiteit Gent | Targeted modified il-1 family members |
| US9732135B2 (en) | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
| MX370565B (es) | 2013-07-19 | 2019-12-17 | Vib Vzw | Miembros de la familia tnf modificados dirigidos. |
| SI3030575T1 (sl) | 2013-08-08 | 2018-11-30 | Cytune Pharma | Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2016187459A1 (en) * | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN110114368B (zh) * | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| EP3576765B1 (en) * | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| KR20260100427A (ko) * | 2018-03-28 | 2026-06-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
-
2018
- 2018-08-08 CN CN202410087979.4A patent/CN117924493A/zh active Pending
- 2018-08-08 US US16/636,250 patent/US12091463B2/en active Active
- 2018-08-08 JP JP2020507609A patent/JP7327885B2/ja active Active
- 2018-08-08 KR KR1020257010936A patent/KR20250049459A/ko active Pending
- 2018-08-08 KR KR1020247012563A patent/KR102793204B1/ko active Active
- 2018-08-08 BR BR112020002706-5A patent/BR112020002706A2/pt unknown
- 2018-08-08 MX MX2020001513A patent/MX2020001513A/es unknown
- 2018-08-08 EP EP18844219.8A patent/EP3665303A4/en active Pending
- 2018-08-08 CN CN201880065737.8A patent/CN111511764B/zh active Active
- 2018-08-08 WO PCT/US2018/045742 patent/WO2019032662A1/en not_active Ceased
- 2018-08-08 IL IL272524A patent/IL272524B1/en unknown
- 2018-08-08 KR KR1020207006788A patent/KR102659140B1/ko active Active
- 2018-08-08 CA CA3069992A patent/CA3069992A1/en active Pending
- 2018-08-08 AU AU2018313810A patent/AU2018313810B2/en active Active
- 2018-08-08 SG SG11202001063QA patent/SG11202001063QA/en unknown
-
2020
- 2020-02-06 MX MX2025009222A patent/MX2025009222A/es unknown
- 2020-02-06 MX MX2025009223A patent/MX2025009223A/es unknown
-
2023
- 2023-03-03 JP JP2023033005A patent/JP7559114B2/ja active Active
-
2024
- 2024-05-20 US US18/668,770 patent/US20240360224A1/en active Pending
- 2024-09-05 US US18/825,514 patent/US20250066486A1/en active Pending
- 2024-09-18 JP JP2024161448A patent/JP7746499B2/ja active Active
-
2025
- 2025-05-01 AU AU2025203121A patent/AU2025203121A1/en active Pending
- 2025-09-17 JP JP2025154319A patent/JP2025181864A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7574348B2 (ja) | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 | |
| JP7522156B2 (ja) | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 | |
| JP2020530298A5 (enExample) | ||
| US9902772B2 (en) | Antibody therapeutics that bind LAG3 | |
| Klener et al. | Immunotherapy approaches in cancer treatment | |
| JP7677908B2 (ja) | 抗ｂｃｍａ免疫療法によりがんを処置するための組成物および方法 | |
| JP2018536431A (ja) | キメラ抗原受容体および使用方法 | |
| JP2020537503A (ja) | 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法 | |
| TW202206453A (zh) | 表現嵌合抗原受體之病毒特異性免疫細胞 | |
| WO2019113221A1 (en) | Engineered proteins to enhance sensitivity of a cell to il-2 | |
| WO2019109838A1 (zh) | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 | |
| EP4577571A1 (en) | Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy | |
| CN115666724A (zh) | 通过施用pd-1抑制剂抗体西米普利单抗来治疗宫颈癌的方法 | |
| CN111944053B (zh) | 抗bcma的car及其表达载体和应用 | |
| JP2025508392A (ja) | 癌免疫療法のための組成物および方法 | |
| WO2023134520A1 (zh) | 靶向人cd40抗原的人源化单克隆抗体及其应用 | |
| US20260000765A1 (en) | CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS | |
| JP2024507866A (ja) | Ｐｄ－１阻害剤を投与することにより肺がんを処置する方法 | |
| WO2024192017A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| JP2024530656A (ja) | 新規Ｔｉｍ－４結合剤の作製及び特性決定 | |
| JP2023542490A (ja) | Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法 | |
| CN118480130A (zh) | 靶向msln的抗体、嵌合抗原受体及其应用 | |
| Cara et al. | Emerging Strategies in CAR-T cell Therapy for Acute Myeloid Leukemia: Overcoming Heterogeneity and Improving Safety through Dual-Antigen Targeting |